Early downregulation of acute phase proteins after doxorubicin exposition in patients with breast cancer
- 216 Downloads
Chemotherapy remains the first-choice option for adjuvant therapy in breast cancer. Here, we investigated the impact of the first chemotherapic cycle of doxorubicin on the plasmatic–proteomic profiling of women diagnosed with breast cancer (n = 87). Blood samples were obtained from the same patient before and after doxorubicin infusion (1 h, 60 mg/m2) and processed for label-free LC-MS proteomic screening. A total of 80 proteins were downregulated after chemotherapy. In silico analysis revealed that the main biological process enrolled was inflammation and canonical pathways involving acute phase proteins. TNF-α, IL-1β, IL-12, TGF-β1, clusterin, and gelsolin were chosen as relevant for further validation. All selected targets presented reduced plasmatic levels after treatment. Our results indicate that doxorubicin downregulated acute phase proteins immediately after its infusion. Since such proteins are cancer promoting, its downregulation could support the effectiveness of doxorubicin along treatment.
KeywordsBreast cancer Doxorubicin Label-free proteomics Cytokines Acute phase proteins Downregulation
The authors are grateful to the Conselho Nacional de Desenvolvimento Tecnológico (CNPq), INCT para o Controle do Câncer and Fundação Araucária for providing the financial support of the study.
Compliance with ethical standards
Conflict of interest
- 3.Prietsman TJ. Results of a prospective clinical trial comparing two cytotoxic regimes containing adriamycin in women with advanced breast cancer. Clin Oncol. 1975;1(3):207–11.Google Scholar
- 4.Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel Monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol. 2009;20(27):4522–9.CrossRefGoogle Scholar
- 15.Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, et al. Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. Br J Cancer. 2010;103(8):1201–8.CrossRefPubMedPubMedCentralGoogle Scholar